Faaiza Arshad
Physician Assistant · Steele, MONPI 1144887001
Payments from drug & device makers
Across 188 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$461
- Otsuka America Pharmaceutical, Inc.$363
- Novo Nordisk$287
- Amgen$283
- Sunovion Pharmaceuticals Inc.$241
- AbbVie$205
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $461 |
| Otsuka America Pharmaceutical, Inc. | 17 | $363 |
| Novo Nordisk | 22 | $287 |
| Amgen | 15 | $283 |
| Sunovion Pharmaceuticals Inc. | 16 | $241 |
| AbbVie | 13 | $205 |
| Lundbeck LLC | 9 | $188 |
| Sumitomo Pharma America, Inc. | 9 | $163 |
| Merck | 7 | $126 |
| AstraZeneca | 8 | $119 |
| Lilly USA, LLC | 7 | $114 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Indivior Inc. | 3 | $64 |
| Pfizer | 2 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Dexcom, Inc. | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 3 | $41 |
| Grifols USA, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Biogen | 1 | $23 |
| Novartis | 1 | $19 |
| Abbott | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| GSK | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Averitas Pharma Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,261 in reported general payments places this provider in the 85th percentile of 1,380 physician assistant providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 40 | $140,161 |
| XifaxanRifaximin | 48 | $66,059 |
| Risperdal ConstaRisperidone Microspheres | 20 | $51,371 |
| EliquisApixaban | 137 | $49,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $38,007 |
| RexultiBrexpiprazole | 20 | $28,387 |
| TrulicityDulaglutide | 23 | $22,767 |
| LinzessLinaclotide | 38 | $21,317 |
| OzempicSemaglutide | 18 | $17,611 |
| JardianceEmpagliflozin | 46 | $17,465 |
| Chlorpromazine Hcl | 44 | $17,304 |
| JanuviaSitagliptin Phosphate | 27 | $15,375 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,335 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $9,568 |
| Paliperidone ErPaliperidone | 34 | $8,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Xarelto | $16 | $199,33795 claims |
| PfizerEliquis | $54 | $49,227137 claims |
| GSKTrelegy Ellipta | $16 | $38,00752 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $363 | $28,38720 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $119 | $26,89873 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $114 | $25,674138 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $25,50668 claims |
| AbbVieLinzess | $205 | $21,31738 claims |
| Novo NordiskOzempic | $287 | $17,61118 claims |
| MerckJanuvia | $126 | $15,37527 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $163 | $8,03116 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $6,33625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Steele
- Jennifer DavissonKansas City$343K
- Andrew BergLees Summit$245K
- Sileen DowisKansas City$117K
- Daniel BeckSikeston$114K
- Amee RozancO Fallon$101K
- Autumn WillsCape Girardeau$37K
- Kimberly BrownSaint Louis$28K
- Marc ReitznerSpringfield$24K
- Justin AllphinOzark$23K
- Jacqueline CastagnoWentzville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.